These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11028835)

  • 21. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.
    Späth M; Stratz T; Neeck G; Kötter I; Hammel B; Amberger CC; Haus U; Färber L; Pongratz D; Müller W
    Scand J Rheumatol; 2004; 33(4):267-70. PubMed ID: 15370724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects on muscle pain by intramuscular injection of granisetron in patients with fibromyalgia.
    Ernberg M; Lundeberg T; Kopp S
    Pain; 2003 Feb; 101(3):275-282. PubMed ID: 12583870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience.
    Kohnen R; Färber L; Späth M
    Scand J Rheumatol Suppl; 2004; 119():67-71. PubMed ID: 15515419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do cytochrome enzymes influence the therapeutic effect of tropisetron in fibromyalgia?
    Stratz T; Kees F; Müller W
    Drugs Exp Clin Res; 2003; 29(2):91-4. PubMed ID: 12951840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice.
    Tolk J; Kohnen R; Müller W
    Scand J Rheumatol Suppl; 2004; 119():72-5. PubMed ID: 15515420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome.
    Seidel MF; Weinreich GF; Stratz T; Müller W
    Rheumatol Int; 2007 Sep; 27(11):1025-30. PubMed ID: 17634903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulatory function of the 5-HT3 receptor antagonist tropisetron.
    Schneider EM; Ma X; Stratz T; Müller W; Lorenz I; Seeling WD
    Scand J Rheumatol Suppl; 2004; 119():34-40. PubMed ID: 15515411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
    Haus U; Späth M; Färber L
    Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists.
    Seidel MF; Müller W
    Expert Opin Pharmacother; 2011 Jun; 12(9):1381-91. PubMed ID: 21323622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting.
    Loewen PS; Marra CA; Zed PJ
    Can J Anaesth; 2000 Oct; 47(10):1008-18. PubMed ID: 11032279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tender points as predictors of distress and the pharmacologic management of fibromyalgia syndrome.
    McCarberg B; Barkin RL; Wright JA; Cronan TA; Groessl E; Schmidt SM
    Am J Ther; 2003; 10(3):176-92. PubMed ID: 12756425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationships among pain and depressive and anxiety symptoms in clinical trials of pregabalin in fibromyalgia.
    Arnold LM; Leon T; Whalen E; Barrett J
    Psychosomatics; 2010; 51(6):489-97. PubMed ID: 21051680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-HT3 receptor antagonists: a new therapeutic approach in rheumatology? Proceedings of a symposium. Frankfurt, Germany, February 12-13, 2004.
    Scand J Rheumatol Suppl; 2004; 119():1-80. PubMed ID: 15584135
    [No Abstract]   [Full Text] [Related]  

  • 36. Economics of serotonin 5-HT3 antagonists.
    Bonneterre J; Bercez C
    Pharmacoeconomics; 1996 Oct; 10(4):433-5. PubMed ID: 10163583
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of tendopathies with tropisetron.
    Stratz T; Varga B; Müller W
    Rheumatol Int; 2002 Nov; 22(6):219-21. PubMed ID: 12426658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.
    Greenshaw AJ; Silverstone PH
    Drugs; 1997 Jan; 53(1):20-39. PubMed ID: 9010647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
    Arnold LM; Palmer RH; Gendreau RM; Chen W
    Psychosomatics; 2012; 53(4):371-9. PubMed ID: 22677218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.
    Späth M; Welzel D; Färber L
    Scand J Rheumatol Suppl; 2000; 113():72-7. PubMed ID: 11028837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.